Stock Update (NASDAQ:PTX): Pernix Therapeutics Holdings Inc Executive Director of Medical and Government Affairs Awarded Prestigious Pain Management Advocacy Award from the ASPMN

Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced that Marsha Stanton, Ph.D., RN, Executive Director of Medical and Government Affairs, was awarded the prestigious Pain Management Advocacy Award from the American Society for Pain Management Nursing® (ASPMN) at the 2016 ASPMN National Conference, which was held in Louisville, KY, from September 7-10, 2016.

“We are proud of Dr. Stanton’s recognition at the ASPMN national conference, and are very pleased to have someone of her caliber as a member of the Pernix Therapeutics team,” said John Sedor, Chairman and CEO of Pernix Therapeutics.

Nominees for the Pain Management Advocacy Award must demonstrate leadership and outstanding contributions which have influenced public perception, attitudes, and awareness of pain and its management through public education, governmental reform, and/or media exposure compatible with the ASPMN mission and goals.

Dr. Stanton is nationally recognized for her extensive work in pain management, including clinical practice, public policy and patient education. She is a registered nurse, and obtained her Master of Science in Health & Human Services from Columbia Pacific University and a Ph.D. in Health Education from Glendale University. (Original Source)

Shares of Pernix Therapeutics closed yesterday at $0.554, up $0.02 or 4.53%. PTX has a 1-year high of $4.54 and a 1-year low of $0.39. The stock’s 50-day moving average is $0.67 and its 200-day moving average is $0.79.

On the ratings front, Brean Capital analyst Difei Yang downgraded PTX to Hold, in a report issued on August 12. According to, Yang has a yearly average return of -8.4%, a 36% success rate, and is ranked #3979 out of 4158 analysts.

Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. The firm distributes its products under the following brands: Treximet, Silenor, Zohydro ER with BeadTek, and Khedezla. 


Stay Ahead of Everyone Else

Get The Latest Stock News Alerts